US Patent

US8536122 — Acylated GLP-1 compounds

Method of Use · Assigned to Novo Nordisk AS · Expires 2026-03-20 · 0y expired

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects the use of acylated GLP-1 compounds, specifically those with a certain number of carbon atoms, in therapeutic applications.

USPTO Abstract

Protracted GLP-1 compounds and therapeutic uses thereof.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2202 — Ozempic
U-2628 — Ozempic
U-2628 — Ozempic
U-3469 — Ozempic
U-2628 — Ozempic
U-2628 — Ozempic
U-2628 — Ozempic
U-2628 — Ozempic
U-3355 — Ozempic
U-2202 — Ozempic

Patent Metadata

Patent number
US8536122
Jurisdiction
US
Classification
Method of Use
Expires
2026-03-20
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.